With respect to the TF pathway inhibitor-1 (TFPI-1), the main inhibitor of the extrinsic coagulation pathway, it has been reported that NSCLC patients with DVT or metastasis had significantly lower levels of this inhibitor than those without DVT or metastasis [127]. This evidence concerns the gene TFPI and deep vein thrombosis.